Literature DB >> 11728362

Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

U Laufs1, S Wassmann, S Hilgers, N Ribaudo, M Böhm, G Nickenig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11728362     DOI： 10.1016/s0002-9149(01)02095-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  36 in total

Review 1.  Isoprenoid metabolism and the pleiotropic effects of statins.

Authors:  Ulrich Laufs; James K Liao
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

2.  Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.

Authors:  Candice Bereal-Williams; Roberto F Machado; Vicki McGowan; Amy Chi; Christian J Hunter; Gregory J Kato; Lori Hunter; Carole K Dalby; Kristine Partovi Hauser; Anitaben Tailor; Richard O Cannon
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 3.  Short-term vascular risk: time to take notice?

Authors:  Liam Smeeth; Aroon D Hingorani
Journal:  Nat Rev Cardiol       Date:  2010-05-04       Impact factor: 32.419

Review 4.  Are lower levels of low-density lipoprotein cholesterol beneficial? a review of recent data.

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

5.  Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia.

Authors:  Gulay S Guven; Enver Atalar; Bunyamin Yavuz; Yavuz Beyazit; Murat Kekilli; Alparslan Kilicarslan; Levent Sahiner; Gul Oz; Necla Ozer; Serdar Aksoyek; Ibrahim C Haznedaroglu; Tumay Sozen
Journal:  J Natl Med Assoc       Date:  2006-04       Impact factor: 1.798

6.  Drug discontinuation effects are part of the pharmacology of a drug.

Authors:  Marcus M Reidenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-08-17       Impact factor: 4.030

Review 7.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 9.  The cardioprotective effects of statins.

Authors:  Jean Davignon
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

10.  HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.

Authors:  Jung-Won Suh; Dong-Ju Choi; Hyuk-Jae Chang; Young-Seok Cho; Tae-Jin Youn; In-Ho Chae; Kwang-Il Kim; Cheol-Ho Kim; Hyo-Soo Kim; Buyng-Hee Oh; Young-Bae Park
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.